利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.018 秒)

    METHOD FOR MAKING ANTIBODY FC-HETERODIMERIC MOLECULES USING ELECTROSTATIC STEERING EFFECTS
    1.
    发明授权
    METHOD FOR MAKING ANTIBODY FC-HETERODIMERIC MOLECULES USING ELECTROSTATIC STEERING EFFECTS 有权

    公开(公告)号：EP3061770B1

    公开(公告)日：2019-12-11

    申请号：EP15187984.8

    申请日：2009-01-06

    申请人： Amgen Inc.

    发明人： KANNAN, Gunasekaran ,  WITTEKIND, Michael

    IPC分类号： C07K16/46

    摘要： The invention relates to methods of making Fc-heterodimeric proteins or polypeptides. The invention also relates to the Fc-heterodimeric proteins or polypeptides themselves, including the individual polypeptide components that comprise the heterodimer. Nucleic acids encoding such polypeptides, expression vectors, and host cells. Moreover, the invention relates to pharmaceutical compositions comprising one of more Fc-heterodimeric proteins or polypeptides.

    METHOD FOR MAKING ANTIBODY FC-HETERODIMERIC MOLECULES USING ELECTROSTATIC STEERING EFFECTS
    3.
    发明公开
    METHOD FOR MAKING ANTIBODY FC-HETERODIMERIC MOLECULES USING ELECTROSTATIC STEERING EFFECTS 有权
    用于生产FC异抗体分子BASED静电所得税影响

    公开(公告)号：EP3061770A1

    公开(公告)日：2016-08-31

    申请号：EP15187984.8

    申请日：2009-01-06

    申请人： Amgen, Inc

    发明人： KANNAN, Gunasekaran ,  WITTEKIND, Michael

    IPC分类号： C07K16/46

    摘要： The invention relates to methods of making Fc-heterodimeric proteins or polypeptides. The invention also relates to the Fc-heterodimeric proteins or polypeptides themselves, including the individual polypeptide components that comprise the heterodimer. Nucleic acids encoding such polypeptides, expression vectors, and host cells. Moreover, the invention relates to pharmaceutical compositions comprising one of more Fc-heterodimeric proteins or polypeptides.

    摘要翻译： 本发明涉及制备异二聚体的Fc蛋白质或多肽的方法。 本发明因此涉及与Fc异源二聚体蛋白质或多肽本身，其中包括单独的多肽成分并包含异源二聚体。 核酸编码的多肽寻求的表达载体和宿主细胞。 更过地，本发明涉及药物组合物，其包括多个Fc异源二聚体蛋白质或多肽的一个。

    AGONISTIC HUMAN LCAT ANTIGEN BINDING PROTEINS AND THEIR USE IN THERAPY
    7.
    发明公开
    AGONISTIC HUMAN LCAT ANTIGEN BINDING PROTEINS AND THEIR USE IN THERAPY 有权
    AGONISTISCHE MENSCHLICHE LCAT-抗原蛋白在IHRE VERWENDUNG IN DER THERAPIE

    公开(公告)号：EP2788384A1

    公开(公告)日：2014-10-15

    申请号：EP12801700.1

    申请日：2012-12-07

    申请人： Amgen Inc.

    发明人： MEININGER, David, P. ,  WITTEKIND, Michael ,  DELANEY, John,M. ,  ZHOU, Mingyue ,  PIPER, Derek, E.

    IPC分类号： C07K16/40 ,  A61K39/395 ,  A61P3/06 ,  A61P9/10

    CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

    摘要： Antigen binding proteins that activate LCAT are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to modulate HDL particle size, increase plasma levels of HDL-C, and increase reverse cholesterol transport. Accordingly, the antigen binding proteins have utility in the treatment and prevention of atherosclerosis, various cardiovascular diseases and cholesterol-related disorders, inflammatory conditions, thrombosis-related conditions, metabolic syndrome, diabetes and insulin-resistance. The LCAT antigen binding proteins are also useful in treating the consequences, symptoms, and/or pathology associated with either genetic or acquired LCAT deficiency, including chronic kidney disease (CKD).

    摘要翻译： 提供激活LCAT的抗原结合蛋白。 还提供了编码抗原结合蛋白的核酸和含有此类核酸的载体和细胞。 抗原结合蛋白在治疗方法中具有价值，其中它可用于调节HDL粒度，增加HDL-C的血浆水平，并增加反向胆固醇转运。 因此，抗原结合蛋白可用于治疗和预防动脉粥样硬化，各种心血管疾病和胆固醇相关疾病，炎性病症，血栓形成相关病症，代谢综合征，糖尿病和胰岛素抵抗。 LCAT抗原结合蛋白也可用于治疗与遗传或获得性LCAT缺乏症（包括慢性肾脏疾病（CKD））相关的后果，症状和/或病理学。

    JACQUELINIDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR
    8.
    发明公开
    JACQUELINIDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR 审中-公开
    使用IL-17受体的前配体组装领域的精确定量和方法

    公开(公告)号：EP2144928A2

    公开(公告)日：2010-01-20

    申请号：EP08746384.0

    申请日：2008-04-20

    申请人： Amgen Inc. ,  The Research Foundation Of State University Of New York

    发明人： GAFFEN, Sarah, L. ,  HANEL, Walter ,  KRAMER, Jill ,  MALONE, James, P. ,  WITTEKIND, Michael ,  PAXTON, Raymond J. ,  SHEN, Fang

    IPC分类号： C07K14/715 ,  A61K39/00

    CPC分类号： C07K14/47 ,  C07K14/7155 ,  C07K2319/00 ,  C07K2319/30

    摘要： The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL- 17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL- 17R family member. Also provided are isolated PLAD- binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.

    摘要翻译： 本发明提供了包含IL-17受体（IL-17R）家族成员的结构域（例如，纤连蛋白III-样结构域）的氨基酸序列的分离的前配体组装域（PLAD）多肽，其中PLAD多肽抑制 包含IL-17R家族成员的受体复合物的多聚化。 还提供了分离的PLAD结合多肽，例如特异性结合本文所述PLAD多肽的抗体和avimers。 本文提供了相关的嵌合蛋白，缀合物，核酸，载体和宿主细胞。 进一步提供了治疗炎症或自身免疫疾病的方法，抑制IL-17介导的信号转导的方法，抑制IL-17配体结合的方法，抑制IL-17R复合物多聚化的方法，以及抑制IL- 提供了至少一种细胞因子，趋化因子，基质金属蛋白酶或与IL-17信号转导相关的其他分子。